Evidence map›Paper›PMID 42523284›Full record

ArticlebioRxiv : the preprint server for biology2026

Single-cell multi-omic analyses resolve the cellular diversity of ALK/ROS1/MET/NTRK-fused gliomas in infants and older children.

Andrea J De Micheli, Carlos O A de Biagi-Junior, Costanza Lo Cascio, Charbel Machaalani, Andreas Postlmayr, Shashank Katiyar, Roeltje R Maas, Venkatesh Kancherla, Regina Reimann, Michal Zápotocký and 14 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Andrea J De MicheliDivision of Oncology and Children's Research Center, University Children's Hospital of Zurich, Zurich, Switzerland.
Carlos O A de Biagi-JuniorDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
Costanza Lo CascioDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
Charbel MachaalaniDivision of Oncology and Children's Research Center, University Children's Hospital of Zurich, Zurich, Switzerland.
Andreas PostlmayrDivision of Oncology and Children's Research Center, University Children's Hospital of Zurich, Zurich, Switzerland.
Shashank KatiyarDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
Roeltje R MaasDivision of Oncology and Children's Research Center, University Children's Hospital of Zurich, Zurich, Switzerland.
Venkatesh KancherlaDivision of Oncology and Children's Research Center, University Children's Hospital of Zurich, Zurich, Switzerland.
Regina ReimannInstitute for Neuropathology, University Hospital Zurich, Zurich, Switzerland.
Michal ZápotockýDepartment of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Liana F NobreDepartment of Paediatrics, University of Alberta, Edmonton, Alberta, Canada.
Sebastian K EderDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
Jacob S RozowskyDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
Théo RibierreNeuroNA Human Cellular Neuroscience Platform, Campus Biotech, Geneva, Switzerland.
Fides ZenkEpigenomics of Neurodevelopment, Brain Mind Institute, School of Life Sciences, Ecole Polytechnique Federale de Lausanne, Ecublens, Switzerland.
Adam ResnickCenter for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Matthew ClarkeNeuropathology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, United Kingdom.
Johannes GojoDepartment of Pediatrics and Adolescent Medicine, Comprehensive Cancer Center and Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.
Uri TaboriArthur and Sonia Labbatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.
Cynthia HawkinsArthur and Sonia Labbatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.
Chris JonesDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Florence M G CavalliInstitut National de la Santé et de la Recherche Médicale (INSERM), U1331 Computational Oncology, Paris, France.
Mariella G FilbinDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
Ana S Guerreiro StücklinDivision of Oncology and Children's Research Center, University Children's Hospital of Zurich, Zurich, Switzerland.

Funding

How the 3D Architecture of the Brain Shapes Cancer Cell Fate DecisionsDP2NS127705 · NINDS · DANA-FARBER CANCER INST · PI FILBIN, MARIELLA GRUBER · 2021 to 2024
$2.7M
NINDS NIH HHS DP2 NS127705
6 · The paper itself

Abstract

Pediatric cancers are thought to arise from dysregulation of developmental programs, otherwise tightly regulated in time and space. Infant-type hemispheric gliomas (IHGs) arise in early childhood, driven by characteristic ALK/ROS1/MET/NTRK receptor tyrosine kinase (RTK) gene fusions. We dissected the cellular hierarchies of 24 fusion-positive gliomas, spanning infants through adolescents, using single-cell and single-nucleus RNA/ATAC-seq, and spatial transcriptomics. We identified five cancer cell states, with radial glia-like cells at the apex of a neoplastic hierarchy resembling neuronal- and glial-like trajectories. Neuronal-like cells were enriched in most IHGs but diminished in ROS1-fused IHGs and older patients. Integration of chromatin profiling revealed FOS/JUN-driven oncogenic programs and high inferred plasticity across all cancer cell populations. Myeloid cells, the most abundant non-neoplastic population, comprised distinct subgroups, suggesting context-dependent functions. Despite lacking high-order structure, spatial transcriptomics revealed discrete cellular niches within IHGs. Collectively, our findings elucidate the cellular states and developmental programs underlying IHGs and RTK-fused gliomas in older patients, opening new avenues for research and therapy innovation.

Identifiers

PMID42523284
PMCPMC13404746

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.